May 29, 2015
Lynn M. Schuchter, MD, FASCO
CHICAGO — Mismatch repair deficiency may be the first genomic marker to predict how patients with cancer will respond to immune checkpoint blockade with the anti–PD-1 antibody pembrolizumab, according to phase 2 study results presented at the ASCO Annual Meeting.
An analysis that included patients with several cancer types showed those with mismatch repair (MMR)-deficient tumors demonstrated a dramatically higher response rate and significantly longer PFS after treatment with pembrolizumab (Keytruda, Merck) than those who did not have the abnormality, characterized as MMR proficient.
In the Journals
May 28, 2015
Monitoring changes in annual serum cancer antigen 125 levels could detect twice the number of women with invasive epithelial ovarian cancer compared with standard…
Cover StoryPublication Exclusive
HemOnc Today, May 25, 2015
Precision medicine has garnered tremendous public attention since President Barack Obama established it as a national priority during his State of the Union address.The…
May 16, 2015
Robert L. Coleman, MD, recently began his 1-year term as president of the Society of Gynecologic Oncology and the Foundation for Gynecologic Oncology.